<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743429</url>
  </required_header>
  <id_info>
    <org_study_id>APN311-304</org_study_id>
    <nct_id>NCT02743429</nct_id>
  </id_info>
  <brief_title>Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma</brief_title>
  <official_title>Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Cancer Research Institute, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, monoclonal anti-Disialoganglioside GD2 (GD2) antibody ch14.18/CHO will be
      assessed for the treatment of patients with relapsed or refractory neuroblastoma. The
      antibody is used as a single agent applied in a new treatment schedule associated with less
      side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Treatment with ch14.18 antibody has demonstrated efficacy in patients with neuroblastoma.
      However the treatment is associated with an on target side effect, i.e. neuropathic pain.
      This requires coadministration of intravenous morphine.

      In this clinical Trial we will evaluate a less toxic treatment regimen consisting of
      continuous longterm Infusion (LTI) of ch14.18/CHO administered at a dose of 10 mg/m2/day over
      10 days (total dose 100 mg/m2/cycle). Patients may receive up to five 35-day cycles in
      absence of signs of progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tumour activity of ch14.18/CHO continuous infusion</measure>
    <time_frame>2 years</time_frame>
    <description>The response rate in patients with measurable/evaluable disease (skeletal lesions, soft tissue lesions, lymph nodes and/or primary tumour site and bone marrow) as measured by Metaiodobenzylguanidine scan (MIBG), Computed tomography (CT), Magnetic Resonance Imaging (MRI) and/or immunocytology at the end of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>2 years</time_frame>
    <description>Pain intensity and the need for appropriate medication for pain relief
Adverse events, vital signs and changes in clinical laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>2 years</time_frame>
    <description>Immunogenicity: Anti-Drug Antibody (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: cells/µl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody dependent cellular cytotoxicity (ADCC)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement dependent cytotoxicity (CDC)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole Blood Test (WBT)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: µg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: l/d*m²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume distribution at steady state (Vdss)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: l/m²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean residence time (MRT)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life time (t1/2)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: µg*d/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) and Minimum Plasma Concentration (Cmin)</measure>
    <time_frame>2 years</time_frame>
    <description>Unit: µg/ml</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Long term infusion of ch14.18/CHO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 day continuous Infusion of ch14.18/CHO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dinutuximab beta</intervention_name>
    <description>Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).
Cycle duration: 35-days.</description>
    <arm_group_label>Long term infusion of ch14.18/CHO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary refractory or relapsed neuroblastoma.

          -  Tumour burden controlled by conventional therapy (except patients with early minimal
             bone marrow relapse).

          -  Measurable and/or evaluable disease in any of the following sites (skeletal lesions,
             soft tissue lesions, lymph nodes and/or primary tumour site and/or bone marrow) as
             measured by mIBG scan, CT, MRI and/or immunocytology.

          -  Patients should have a life expectancy of at least 12 weeks.

        Exclusion Criteria:

          -  Progressive disease at the time of inclusion into the study.

          -  ADA positivity due to previous treatment with an anti-GD2 antibody (e.g. ch14.18/Mouse
             myeloma cell line SP2/0 (SP2/0), ch14.18/CHO).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Holger Lode, Professor</last_name>
    <phone>+49 3834 86 6301</phone>
    <email>lode@uni-greifswald.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Pasewald</last_name>
    <phone>+49 3834 86 19463</phone>
    <email>sandra.pasewald@uni-greifswald.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medicine Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger N. Lode, Professor</last_name>
      <phone>+49 3834 86 6301</phone>
      <email>lode@uni-greifswald.de</email>
    </contact>
    <contact_backup>
      <last_name>Silke Kietz, MD</last_name>
      <phone>+49 3834 86 6309</phone>
      <email>silke.kietz@uni-greifswald.de</email>
    </contact_backup>
    <investigator>
      <last_name>Karoline Ehlert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ch14.18/CHO</keyword>
  <keyword>neuroblastoma</keyword>
  <keyword>long term infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

